Editorial
Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
Translational Lung Cancer Research
2020;
9
(1)
:1-3
.
(25 February 2020)
Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(1)
:4-7
.
(25 February 2020)
What’s in a (tumor) cavity?
Translational Lung Cancer Research
2020;
9
(1)
:8-9
.
(25 February 2020)
Original Article
Low-dose CT lung cancer screening in never-smokers and smokers: results of an eight-year observational study
Translational Lung Cancer Research
2020;
9
(1)
:10-22
.
(25 February 2020)
Comparison of autofluorescence and white-light bronchoscopies performed with the Evis Lucera Spectrum for the detection of bronchial cancers: a meta-analysis
Translational Lung Cancer Research
2020;
9
(1)
:23-32
.
(25 February 2020)
Extent of resection and lymph node evaluation in early stage metachronous second primary lung cancer: a population-based study
Translational Lung Cancer Research
2020;
9
(1)
:33-44
.
(25 February 2020)
Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma
Translational Lung Cancer Research
2020;
9
(1)
:45-54
.
(25 February 2020)
A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(1)
:55-60
.
(25 February 2020)
Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications
Translational Lung Cancer Research
2020;
9
(1)
:61-70
.
(25 February 2020)
Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
Translational Lung Cancer Research
2020;
9
(1)
:71-81
.
(25 February 2020)
The prognostic effect of TTF-1 expression in the Chinese population of patients with advanced lung adenocarcinomas
Translational Lung Cancer Research
2020;
9
(1)
:82-89
.
(25 February 2020)
Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study)
Translational Lung Cancer Research
2020;
9
(1)
:90-102
.
(25 February 2020)
Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution
Translational Lung Cancer Research
2020;
9
(1)
:103-110
.
(25 February 2020)
Review Article
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Translational Lung Cancer Research
2020;
9
(1)
:111-138
.
(25 February 2020)
Case Report
Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
Translational Lung Cancer Research
2020;
9
(1)
:139-143
.
(25 February 2020)
Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
Translational Lung Cancer Research
2020;
9
(1)
:144-147
.
(25 February 2020)
Editorial Commentary
KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(1)
:148-153
.
(25 February 2020)
Letter to the Editor
Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer
Translational Lung Cancer Research
2020;
9
(1)
:154-155
.
(25 February 2020)
Cavity development: a potential biomarker for antiangiogenesis agents
Translational Lung Cancer Research
2020;
9
(1)
:156-157
.
(25 February 2020)
What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
Translational Lung Cancer Research
2020;
9
(1)
:158-159
.
(25 February 2020)
Treatment failure patterns of adjuvant gefitinib therapy and minimal residual disease detection in resected EGFR-mutant non-small cell lung cancer: author’s reply
Translational Lung Cancer Research
2020;
9
(1)
:160-162
.
(25 February 2020)
